在早期试验结果中,CASI Pharma的CID-103在73%的成年人中增加了血小板数量,而这些人血小板数量很低,难以治疗,而且具有安全性. CASI Pharma's CID-103 boosted platelets in 73% of adults with hard-to-treat low platelet counts, with a safe profile, in early trial results.

CASI制药公司在2025年12月7日的ASH会议上报告了CID-103(一种反CD38抗体)在11名患有抗治疗性免疫性血栓细胞障碍症的成年人中进行的CID-103(一种抗CD38抗体)第一阶段试验结果。 CASI Pharmaceuticals reported interim Phase 1 trial results for CID-103, an anti-CD38 antibody, in 11 adults with treatment-resistant immune thrombocytopenia at the ASH meeting on December 7, 2025. 该药物展示了可管理的安全情况,没有剂量限制毒性,只有两起3级不利事件。 The drug showed a manageable safety profile with no dose-limiting toxicities and only two Grade 3 adverse events. 11名病人中有8名(73%)达到了持续改进小板计数的首要功效目标,6名病人实现了完全反应,有些病人在治疗后一周内就得到完全反应。 Eight of 11 patients (73%) met the primary efficacy goal of sustained platelet count improvement, with six achieving complete response, some as early as one week after treatment. 与CID-103机制一致的关键免疫细胞和抗体的减少量。 Reductions in key immune cells and antibodies aligned with CID-103’s mechanism. 该研究正在FDA和中国监管机构的批准下进行,支持自身免疫性疾病和移植拒绝的进一步发展. The study is ongoing under FDA and Chinese regulatory approvals, supporting further development in autoimmune diseases and transplant rejection.